50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Pathogenesis and Treatment of Hemophilic Inhibitors

Monday, December 8, 2008: 7:00 AM-9:00 AM

3020-3022-3024 - West (Moscone Center)

Moderators:

David Lillicrap, MD and Alisa S. Wolberg, PhD

7:00 AM

Investigating the Mechanisms Underlying FVIII Antibody Production in Hemophilic Mice Following Recombinant and Plasma-Derived FVIII Infusion

Mohammad Qadura, BSc^*, Braden Waters, BSc^*, Erin Burnett, BSc^*, Rouzbeh Chegeni, BSc, MSc, PhD^*, Maha Othman, PhD, MD and David Lillicrap, MD

Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada

7:15 AM

238

Requirements for Co-Stimulation in T-Cell Dependent and T-Cell Independent Re-Stimulation of FVIII-Specific Memory B Cells

Aniko Ginta Pordes¹^*, Christina Hausl, PhD¹^*, Peter Allacher²^*, Rafi Uddin Ahmad, PhD²^*, Eva M Muchitsch, PhD²^*, Hartmut J Ehrlich, MD²^*, Hans Peter Schwarz, MD² and Birgit M Reipert, PhD²^*

¹BMT Research GesmbH, Vienna, Austria
²Baxter BioScience, Vienna, Austria

7:30 AM

239

Factor Xa Variants as Novel Bypass Agents for the Treatment of Hemophilia in Murine Models

Lacramioara Ivanciu, Ph.D., Raffaella Toso, Ph.D.^*, Alexander Schlachterman, M.D.^*, Harre Downey, B.S.^*, Jian-Hua Liu, B.S.^*, Valder R. Arruda, M.D., Ph.D. and Rodney M. Camire, Ph.D.

Hematology, Children's Hospital of Philadelphia, Philadelphia, PA

7:45 AM

240

Zymogen-Like Factor Xa Variants Restore Thrombin Generation and Effectively Bypass the Intrinsic Pathway in Vitro

Matthew W Bunce, Ph.D.^*, Raffaella Toso, Ph.D.^*, Valder R. Arruda, M.D., Ph.D. and Rodney M. Camire, Ph.D.

Hematology, Children's Hospital of Philadelphia, Philadelphia, PA

8:00 AM

241

Anti-CD3 Therapy Expands the CD4⁺CD25⁺ Compartment in Hemophilia a Mice Inducing Tregs That Potently Prevent Factor VIII Inhibitor Formation

Braden Waters, B.Sc.H^*, Mohammad Qadura, B.Sc.H^*, Erin Burnett^*, Rouzbeh Chegeni, PhD^*, Andrea Labelle^*, Patrick Thompson^* and David Lillicrap, MD

Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada

8:15 AM

242

Presence of Factor V Leiden or Prothrombin Mutation Influence Inhibitor Development in Children with Severe Hemophilia A: Data of a Multicenter Cohort Study

Karin Kurnik, Dr.¹^*, Christoph Bidlingmaier, Dr.¹^*, Christine During²^*, Susan Halimeh³^*, Rosemarie Schobess⁴^* and Ulrike Nowak-Gottl, MD⁵

¹Pediatric Hemophilia Centre, Dr. v. Hauner's Children's University Hospital, Munich, Germany
²Ped. Hematol/Oncol, Univ. of Munster, Munster, Germany
³Hemophila treatment centre, MVZ Duisburg, Duisburg, Germany
⁴MVZ Leibzig, Leipzig, Germany
⁵Dept. of Pediatric Hem./Onc., University Children's Hospital, Munster, Germany

8:30 AM

243

Induction of Immune Tolerance to Canine FVIII in Hemophilia a Dogs with Inhibitors Using AAV-Mediated Expression of Canine FVIII

Jonathan D Finn, PhD¹^*, Denise E Sabatino, PhD²^*, Margareth C Ozelo, MD³^*, Shangzhen Zhou, MD¹^*, David Lillicrap, MD³, Haig H Kazazian, MD²^*, Timothy C. Nichols, MD⁴ and Valder R. Arruda, M.D., Ph.D.⁵

¹Hematology, Children's Hospital of Philadelphia, Philadelphia, PA
²Genetics, University of Pennsylvania School of Medicine, Philadelphia
³Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada
⁴Francis Owen Blood Research Lab, University of North Carolina, Chapel Hill, NC
⁵Hematology, University of Pennsylvania/Children's Hospital of Philadelphia, Philadelphia, PA

8:45 AM

244

IL-17 Is Secreted by T-Cell Clones Isolated Following An Initial Peak Inhibitor Response to Factor VIIII, Suggesting Th17 Cells Play a Role in Inhibitor Development

Ruth A. Ettinger, Ph.D.¹^*, Eddie James, Ph.D.²^*, William W. Kwok, Ph.D.²^*, Arthur R. Thompson, M.D., Ph.D.¹ and Kathleen P. Pratt, Ph.D.¹

¹Puget Sound Blood Center, Seattle, WA
²Benaroya Research Institute, Seattle, WA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

322.O1.8 Pathogenesis and Treatment of Hemophilic Inhibitors